Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.53 |
| ▸ | ACE | P12821 | 4/20 | 0.53 |
| ▸ | CPA1 | P15085 | 3/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP7 | P09237 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 1/20 | 0.52 |
| ▸ | CTSC | P53634 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27852469 | 1.00 | MME (0.53) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL29658158 | 0.94 | MME (0.50) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL30054155 | 0.91 | MME (0.56) | MMEACECPA1ACE2CTSC | |
| SCHEMBL30051579 | 0.91 | MME (0.55) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL30055181 | 0.91 | MME (0.49) | MMEACECPA1ACE2CTSC | |
| SCHEMBL30880912 | 0.91 | CTSB (0.52) | MMEACECPA1ACE2MMP2 | |
| SCHEMBL29517104 | 0.90 | ACE (0.55) | MMEACECPA1ACE2 | |
| SCHEMBL31064821 | 0.89 | BACE1 (0.51) | MMEACECPA1ACE2 | |
| SCHEMBL30051541 | 0.88 | ACE (0.64) | MMEACECPA1ACE2 | |
| SCHEMBL8021459 | 0.87 | MME (0.57) | MMEACECPA1ACE2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518794-B2 | Synthesis method for liraglutide with low racemate impurity | Shenzhen JYMed Technology Co., Ltd. (CN) | 2022-12-06 | — | — | US | claimed |
| CN-108697767-B | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | 安塔罗斯医疗公司 | 2022-04-15 | — | — | CN | claimed |
| EP-3765629-B1 | KINASE AND/OR PHOSPHATASE SENSING VIA HYDROXYQUINOLINE-SENSITIZED CHELATES | MASSACHUSETTS INST TECHNOLOGY (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-112105742-B | Sensing of kinases and/or phosphatases by hydroxyquinoline sensitized chelates | 麻省理工学院 | 2024-11-29 | — | — | CN | disclosed |
| US-11518794-B2 | Synthesis method for liraglutide with low racemate impurity | Shenzhen JYMed Technology Co., Ltd. (CN) | 2022-12-06 | — | — | US | disclosed |
| CN-108697767-B | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | 安塔罗斯医疗公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-101511364-B | Combination treatment for diabetes mellitus | NYCOMED GMBH | 2012-08-15 | — | — | CN | disclosed |
| CN-101137368-B | Roflumilast for the treatment of diabetes | NYCOMED GMBH | 2012-05-16 | — | — | CN | disclosed |